Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,846 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,846 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT05167409 | Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | terminated | Phase 2 | 19 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04034173 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | terminated | Phase 2 | 3 | Ludwig-Maximilians - University of MunichOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer(Neo-POLEM) | terminated | Phase 2 | 3 | University of SouthamptonOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | terminated | Phase 2 | 7 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT01408407 | Alkagin Paste in the Prevention of Radiation Dermatitis | terminated | Phase 2 | 2 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers(TEJAS-2) | terminated | Phase 2 | 29 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | terminated | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | terminated | Phase 2 | 76 | Inspirna, Inc.INDUSTRY | 3 | Feb 20, 2026 | clinicaltrials |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery | terminated | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | terminated | Phase 2 | 5 | Replimune, Inc.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | terminated | Phase 2 | 6 | Chloe Atreya, MD, PhDOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT02982694 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | terminated | Phase 2 | 46 | Vall d'Hebron Institute of OncologyOTHER | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05350501 | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer(CLAUDE) | terminated | Phase 2 | 1 | EnteromeINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | terminated | Phase 1 / Phase 2 | 175 | Bolt Biotherapeutics, Inc.INDUSTRY | 4 | Sep 15, 2025 | clinicaltrials |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | terminated | Phase 2 | 180 | NuCana plcOTHER | 6 | Sep 12, 2025 | clinicaltrials |
| NCT00766142 | Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer(COCHISE) | terminated | Phase 2 | 18 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05619172 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | terminated | Phase 2 | 16 | SOTIO Biotech AGINDUSTRY | 3 | Jul 24, 2025 | clinicaltrials |
| NCT03547999 | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | terminated | Phase 2 | 17 | Patrick BolandOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | terminated | Phase 2 | 6 | University of FloridaOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)(ELEVATE CRC) | terminated | Phase 2 | 77 | Gilead SciencesINDUSTRY | 10 | Jul 1, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04479436 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | terminated | Phase 2 | 40 | Daiichi SankyoINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | terminated | Phase 2 / Phase 3 | 62 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT01550510 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | terminated | Phase 1 / Phase 2 | 4 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04853043 | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer(APK Mutant) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT04450836 | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer(SOREGATT) | terminated | Phase 2 | 234 | UNICANCEROTHER | 2 | Mar 30, 2025 | clinicaltrials |
| NCT04952753 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC(daNIS-3) | terminated | Phase 2 | 204 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 26, 2025 | clinicaltrials |
| NCT06834399 | TATE and KN046 in MCRC | terminated | Phase 2 | 42 | Zhejiang Raygene Pharmaceuticals Co., LtdINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials